Wall Street Journal: February 12, 2019. At a recent FDA meeting, surgical mesh with the intended use in pelvic organ prolapse was reviewed. NCHR testified.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Policing Big Pharma’s Influence Over Doctors’ Treatment Guidelines
Undark: February 4, 2019. Medical treatment guidelines are supposed to advise doctors how best to treat their patients. But what if the guidelines are written by doctors who are paid by particular pharmaceutical or device companies? Even if your doctor doesn’t take money from Pharma, how will biased guidelines affect what your doctor recommends to your treatment?
Read More »Hundreds of EpiPen Users Complained About Problems With the Lifesaving Device. It Still Took 3 Years and a Top Regulator Stepping in Before Serious Change — With Potentially Deadly Outcomes
Business Insider: February 1, 2019. When hundreds of patients reported that their EpiPens were defective, Mylan blamed the patients rather than apologizing and fixing the problems. NCHR president tells Business Insider what she thinks of that excuse.
Read More »Municipal and Schools Budgets Proposed for FY ’19-20, Public Comments Focus on Turf, Ice Rink
Greenwich Free Press: January 25, 2019. NCHR’s president, Dr. Zuckerman, traveled to Connecticut to present information on artificial turf fields.
Read More »J&J hit with $120M bill in 46-state hip implant marketing settlement
MedTech Dive: January 23, 2019. After many reports of faulty hip implants, Johnson & Johnson are finally being charged for damages.
Read More »